Clinical Trial Update: Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating safety and efficacy of switching virologically suppressed women to a fixed-dose combination of B/F/TAF from several alternate re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• ATV+RTV+FTC/TDF (atazanavir/ritonavir/emtricitabine/tenofovir disoproxil fumarate)
• B/F/TAF (emtricitabine/tenofovir alafenamide/cobicistat-darunavir)
• E/C/F/TAF (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)
• E/C/F/TDF (emtricitabine/tenofovir disoproxil fumarate/cobicistat/elvitegravir)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV-1 Infection | Phase 3 | Status: COMPLETED | Results posted: 2018-11-02